Bolt Biotherapeutics
Bolt Biotherapeutics is developing its novel BoltbodyTM platform, a cancer immunotherapy that consists of Immune-Stimulating Antibody Conjugates (ISAC).
2
Funding Rounds
$147.5m
Money raised
Overview
Bolt Biotherapeutics is developing its novel BoltbodyTM platform, a cancer immunotherapy that consists of Immune-Stimulating Antibody Conjugates (ISAC).
-
Website:
- Business model: B2B
- Social accounts:
Funding series
Funding Series Analysis
The company Bolt Biotherapeutics has raised a total of $93.5m in funding over 2 rounds.
Key Insights:
- Bolt Biotherapeutics, Inc. Series C round, July 2020: $93.5m
- Bolt Biotherapeutics Series B round, February 2019: $54m
Bolt Biotherapeutics, Inc. Series C round, July 2020
$93.5m
Bolt Biotherapeutics Series B round, February 2019
$54m
Industries
Bolt Biotherapeutics is active in the following industries: